HCA Healthcare UK has treated a metastatic lung cancer patient with tumour-infiltrating lymphocyte (TIL) therapy for the first time as part of a clinical trial at its research arm, Sarah Cannon Research Institute UK. TIL therapy, which involves using a patient’s own immune cells to attack cancer, was approved by the US Food and Drug…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2026 All rights reserved LaingBuisson
 therapy for the first time as part of a clinical trial at its research arm, Sarah Cannon Research Institute UK.){kind=link}